SCHEMBL10245110

SCHEMBL10245110

CCCCNC(=O)c1nccc2ccccc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.67
HTT P42858 2/20 0.53
TSHR P16473 1/20 0.53
DRD2 P14416 2/20 0.52
DRD3 P35462 2/20 0.52
SMN1; SMN2 Q16637 3/20 0.49
NPC1 O15118 1/20 0.49
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48
HDAC5 Q9UQL6 1/20 0.48
CNR2 P34972 1/20 0.48
NCEH1 Q6PIU2 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5020895 0.96 RAB9A (0.66) RAB9AHTTTSHRDRD2DRD3
SCHEMBL25112299 0.92 RAB9A (0.71) RAB9ATSHRDRD2DRD3HDAC3
SCHEMBL24898159 0.85 RAB9A (0.66) RAB9ATSHRDRD2DRD3HDAC3
SCHEMBL10244761 0.82 SMN1; SMN2 (0.49) RAB9AHTTTSHRSMN1; SMN2NPC1
SCHEMBL4097649 0.79 RAB9A (0.61) RAB9ATSHRDRD2DRD3SMN1; SMN2
SCHEMBL15659736 0.79 RAB9A (0.47) RAB9AHTTDRD2DRD3HDAC3
SCHEMBL15660540 0.79 RAB9A (0.47) RAB9AHTTDRD2DRD3HDAC3
SCHEMBL15657797 0.79 RAB9A (0.47) RAB9AHTTDRD2DRD3HDAC3
SCHEMBL15657659 0.79 RAB9A (0.47) RAB9AHTTDRD2DRD3HDAC3
SCHEMBL15661683 0.79 RAB9A (0.47) RAB9AHTTDRD2DRD3HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 RAB9A 5/4885HTT 868/4885TSHR 1567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.